Evaluation of Pancreatic Duct Stenting in Patients With Pancreatic Pseudocysts.

Randomized Multicenter Study on Pancreatic Duct Stenting in Disrupted or Obstructed Ducts in Context With Endoscopic Treatment of Pancreatic Pseudocysts.

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01276002

Acronym

Disduct

Enrollment

Registered

2011-01-13

Start date

2011-01-31

Completion date

2016-12-31

Last updated

2022-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Acute Pancreatitis

Keywords

disrupted duct, pancreatic pseudocysts

Brief summary

The disruption of the pancreatic duct seems to be a major cause pseudocyst formation and persistence in patients suffering from acute/chronic pancreatitis. No prospective randomized studies have been conducted on the influence of pancreatic duct stenting for the patients' benefits and recurrence rates. The aim fo this study is therefore to evaluate prospectively in a randomized, controlled fashion in patients wit pancreatic pseudocysts, wether pancreatic duct stenting of a disrupted pancreatic duct is beneficial in terms of quicker clinical recovery and avoidance of recurrence of pancreatic pseudocysts.

Interventions

PROCEDUREpancreatic duct stenting

in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* pancreatic pseudocyst, at least 6 cm in diameter * symptomatic pancreatic pseudocyst * increasing size of pancreatic pseudocyst within 6 weeks

Exclusion criteria

* Pregnancy * Age less than 18 years * Postoperative status preventing access to papilla * Allergy to contrast preventing from ERP * Missing informed consent to study * PTT above 1.5 times of normal, unless substituted * Platelet count less than 50.000/µl, unless substituted * Pancreatic ascites or fistula * Life expectancy less than 2 years * Percutaneously drained cysts are not part of the study

Design outcomes

Primary

Measure	Time frame
Recurrence of pancreatic pseudocyst	two years

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026